(2S)-2-hydroxy-3-(4-isothiocyanatophenoxy)-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-2-hydroxy-3-(4-isothiocyanatophenoxy)-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
• 化学式: C₁₈H₁₄F₃N₃O₅S
• 分子量: 441.387
• InChiKey: SJWMTXJQSDNMAN-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  149
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  (S)-{4-[2-hydroxy-2-(4-nitro-3-trifluoromethylphenylcarbamoyl)propoxy]phenyl}carbamic acid tert-butyl ester 在 碳酸氢钠 、 乙酰氯 作用下， 以 乙醇 、 氯仿 、 水 为溶剂， 生成 (2S)-2-hydroxy-3-(4-isothiocyanatophenoxy)-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  参考文献：
  名称：

  前列腺癌的芳基异硫氰基选择性雄激素受体调节剂（SARM）。

  摘要：

  制备了一系列新的雄激素受体靶向剂（ARTA），并在雄激素依赖性和非依赖性前列腺癌细胞系中进行了测试。这些试剂是具有异硫氰酸根基取代的B环的比卡鲁胺类似物。同样，R-比卡鲁胺的连接基砜被保持或替换为几个可选的连接基，包括醚，胺，N-甲胺，硫醚和亚甲基（在这种情况下，该产品是外消旋混合物）在X位置的官能团。为了扩大这些芳基异硫氰酸根基AR配体的结构活性关系（SAR），还制备并测试了B环卤代芳基异硫氰酸根基配体。芳基异硫氰酸根基AR配体对AR的结合亲和力范围为0.6到54 nM。其中，硫醚和醚键表现出高结合亲和力（0.6和4.6 nM，与雄激素非依赖性前列腺癌细胞系（DU145，PC-3和PPC-1）相比，对LNCaP（一种雄激素依赖性前列腺癌细胞系）分别具有选择性和选择性的细胞生长抑制作用（约3至6倍），并且膀胱细胞系（TSU-Pr1）。但是，配体在正常猴肾细胞系（CV-1）中是无活性的（IC50>

  DOI：

  10.1016/j.bmc.2006.06.019

文献信息

• Design, Synthesis, and Biological Characterization of Metabolically Stable Selective Androgen Receptor Modulators
  作者：Craig A. Marhefka、Wenqing Gao、Kiwon Chung、Juhyun Kim、Yali He、Donghua Yin、Casey Bohl、James T. Dalton、Duane D. Miller

  DOI：10.1021/jm030336u

  日期：2004.2.1

  A series of nonsteroidal ligands were synthesized as second-generation agonists for the androgen receptor (AR). These ligands were designed to eliminate metabolic sites identified in one of our first-generation AR agonists, which was inactive in vivo due to its rapid metabolism to inactive constituents. The binding affinity of these compounds was evaluated using AR isolated from rat ventral prostate. These second-generation compounds bound the AR in a high affinity and stereoselective manner, with K-i values ranging from about 4 to 130 nM. The ability of these ligands to stimulate AR-mediated transcriptional activation was examined in cells transfected with the human AR and a hormone-dependent luciferase reporter gene. Although some compounds were unable to stimulate AR-mediated transcription, several demonstrated activity similar to that of dihydrotestosterone (DHT, an endogenous steroidal ligand for the AR). We also evaluated the in vivo pharmacologic activity of selected compounds in castrated male rats. Three compounds were identified as selective androgen receptor modulators (SARMs), exhibiting significant anabolic activity while having only moderate to minimal androgenic activity in vivo.
• Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
  申请人：Dalton James T.

  公开号：US20080193380A1

  公开（公告）日：2008-08-14

  Provided is a class of radiolabeled androgen receptor targeting agents (ARTA), useful for prostate cancer imaging and in treating or preventing prostate cancer. The agents define a new subclass of radiolabeled compounds, which are selective androgen receptor modulators (SARM), which demonstrate antiandrogenic activity of a nonsteroidal ligand for the androgen receptor, and/or which bind irreversibly to the androgen receptor. The present invention further provides methods for a) imaging of cancer in a subject, b) imaging an androgen receptor-containing tissue in a subject, c) in-vivo imaging in a subject, d) treating a subject suffering from prostate cancer, e) delaying the progression of prostate cancer in a subject suffering from prostate cancer, f) preventing the recurrence of prostate cancer in a subject suffering from prostate cancer, and g) treating the recurrence of prostate cancer in a subject suffering from prostate cancer, which comprise using the radiolabeled compounds of the present invention. The present invention further provides a method of producing the radiolabeled SARM compounds, and precursor compounds useful in the preparation of the radiolabeled SARM compounds.
• Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer
  作者：Dong Jin Hwang、Jun Yang、Huiping Xu、Igor M. Rakov、Michael L. Mohler、James T. Dalton、Duane D. Miller

  DOI：10.1016/j.bmc.2006.06.019

  日期：2006.10

  the linker sulfone of R-bicalutamide was maintained or replaced with several alternative linkages including ether, amine, N-methylamine, thioether, and methylene (in this case the product was a racemic mixture) functional groups at the X-position. To expand the structure-activity relationship (SAR) of these arylisothiocyanato AR ligands, B-ring halogenated arylisothiocyanato ligands were also prepared

  制备了一系列新的雄激素受体靶向剂（ARTA），并在雄激素依赖性和非依赖性前列腺癌细胞系中进行了测试。这些试剂是具有异硫氰酸根基取代的B环的比卡鲁胺类似物。同样，R-比卡鲁胺的连接基砜被保持或替换为几个可选的连接基，包括醚，胺，N-甲胺，硫醚和亚甲基（在这种情况下，该产品是外消旋混合物）在X位置的官能团。为了扩大这些芳基异硫氰酸根基AR配体的结构活性关系（SAR），还制备并测试了B环卤代芳基异硫氰酸根基配体。芳基异硫氰酸根基AR配体对AR的结合亲和力范围为0.6到54 nM。其中，硫醚和醚键表现出高结合亲和力（0.6和4.6 nM，与雄激素非依赖性前列腺癌细胞系（DU145，PC-3和PPC-1）相比，对LNCaP（一种雄激素依赖性前列腺癌细胞系）分别具有选择性和选择性的细胞生长抑制作用（约3至6倍），并且膀胱细胞系（TSU-Pr1）。但是，配体在正常猴肾细胞系（CV-1）中是无活性的（IC50>